Building prediction models for moderate to severe thyroid eye disease
Develops models to predict moderate to severe thyroid-associated ophthalmopathy in adults.
Key facts
- Who runs it
- Shanghai Changzheng Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 9 Oct 2024
- Expected to end
- 6 Sept 2028
- Type of study
- Observational
- Record updated
- 24 June 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- According to the Bartley criteria,diagnosed TAO at our hospital after 2024/8/31
- Moderate to severe patients defined by EUGOGO
- CAS ≥3 (on the 7-item scale) for the study eye
Who cannot take part
- History of systemic (eg, oral or IV) steroid use with a cumulative dose equivalent to \>1 g of methylprednisolone for the treatment of TAO
- Any major illness/condition or evidence of an unstable clinical condition that, in the investigator\'s judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
- Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participant\'s participation in the study
- Any other condition that,would impair the ability of the participant to undergo orbital MRI
- Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
- Pregnant or lactating
- Incomplete information
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO.
Read full original descriptionShow less
The aim of this clinical study is to:
1. Found the new diagnostic markers or imaging sequences. 2. Establish and validate a multimodal and multiparameter prediction model for moderate to severe TAO.
The group in the trial
- TAO
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Establishment of Multiparametric Prediction Models for Moderate to Severe Thyroid Associated Ophthalmopathy
- Plain-language title
- Building prediction models for moderate to severe thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
- Fit questions
- Built from NCT06590220, who can take part
- Record updated
- 24 June 2025